evaluation of microvascular dysfunction in patients with Takotsubo syndrome

An Uncontrolled, Open-label, Exploratory Trial Investigating Temporal Changes in Microcirculatory Dysfunction in Patients with Takotsubo Syndrome Using Pressurewire X

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1032230520

Enrollment

Registered

2023-12-19

Start date

2023-12-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

takotsubo syndrome takotsubo syndrome,Microvascular Angina,Coronary spasm angina

Interventions

To evaluate coronary artery microcirculatory resistance and coronary flow reserve changes during th e acute and recovery phases of patients with Takotsubo syndrome using the CoroFlow system (Abbo tt).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This clinical trial sets two stages of selection criteria, primary registration and secondary registration, and targets patients who meet all the criteria at each stage. Primary registration is conducted for patients suspected of having Takotsubo syndrome. Secondary registration is conducted after catheter examination. Primary Registration: 1, Adults aged 18 and over at the time of consent acquisition. 2, Patients who have received sufficient explanation about participating in this trial, have a full understanding, and have obtained written consent by their own free will or that of a proxy. 3, Patients who are hospitalized at Chiba University Hospital, or are scheduled to be hospitalized after a cardiac catheter examination. 4, Patients suspected of having Takotsubo syndrome based on primary examinations (electrocardiogram, echocardiogram, blood tests, etc.). Secondary Registration: 1, Patients diagnosed with Takotsubo syndrome as a result of cardiac catheter examination, and who can continue to measure IMR and CFR ( if possible, assessment of the CS-Lac/Ao-Lac ratio ).

Exclusion criteria

Exclusion criteria: Patients conflicting with any of the following will not be included in this clinical trial: 1, Patients from whom consent cannot be obtained, either from themselves or a proxy. 2, Patients deemed unsuitable as subjects by the trial responsible (sub) physician.

Design outcomes

Primary

Measure	Time frame
Changes over time (acute phase - after 3 months) in microvascular resistance index by pressurewireX (Abbott)	—

Secondary

Measure	Time frame
Changes over time (acute phase - after 3 months)in coronary flow reserve obtained by pressurewireX (Abbott), and the ratio of lactate levels of blood obtained from coronary sinus and aorta over time	—

Contacts

Public ContactGoto Hiroki

Chiba University Hospital

cdca0048@chiba-u.jp+81-43-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026